Ratings by Northland (Carl Byrnes)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/29/2025 | Durect Corp | DRRX | Downgrade | Market Perform (Outperform) |
0.55 (1.91) |
247.27% | Details | |
| 7/22/2025 | Connect Biopharma Holdings Ltd | CNTB | Maintain | Outperform (N/A) |
|
Details | ||
| 4/30/2025 | TriSalus Life Sciences, Inc. | TLSI | Maintain | Outperform (N/A) |
|
Details | ||
| 3/20/2025 | Alvotech SA | ALVO | Maintain | Outperform (N/A) |
|
Details | ||
| 3/17/2025 | Spectral AI | MDAI | Maintain | Outperform (N/A) |
|
Details | ||
| 10/25/2024 | TriSalus Life Sciences, Inc. | TLSI | New Coverage | Outperform (N/A) |
4.11 (4.47) |
8.76% | Details | |
| 9/12/2024 | Oncternal Therapeutics | ONCT | Downgrade | Market Perform (Outperform) |
4.16 (0.53) |
-87.26% | Details | |
| 5/16/2024 | Heron Therapeutics | HRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/21/2023 | Envoy Medical | COCH | New Coverage | Outperform (N/A) |
2.25 (0.65) |
-71.11% | Details | |
| 11/8/2023 | Durect Corp | DRRX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/14/2023 | Durect Corp | DRRX | New Coverage | Outperform (N/A) |
2.90 (1.91) |
-34.14% | Details | |
| 8/1/2023 | Esperion Therapeutics | ESPR | Upgrade | Market Perform (Underperform) |
1.57 (2.73) |
73.89% | Details | |
| 7/19/2023 | Amarin Corporation | AMRN | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/22/2023 | Cardio Diagnostics Holdings, Inc. | CDIO | New Coverage | Outperform (N/A) |
1.42 (5.30) |
273.24% | Details | |
| 3/16/2023 | Esperion Therapeutics | ESPR | Downgrade | Underperform (Market Perform) |
3.98 (1.57) |
-60.55% | Details | |
| 1/6/2023 | Nabriva Therapeutics AG | NBRV | Downgrade | Underperform (Outperform) |
2.36 (1.42) |
-39.83% | Details | |
| 12/28/2022 | PolarityTE | PTE | Maintain | Outperform (N/A) |
|
Details | ||
| 11/23/2022 | Opiant Pharma | OPNT | Downgrade | Market Perform (Outperform) |
20.09 (20.65) |
2.79% | Details | |
| 11/23/2022 | Aridis Pharmaceuticals | ARDS | Maintain | Outperform (N/A) |
|
Details | ||
| 11/14/2022 | Opiant Pharma | OPNT | Maintain | Outperform (N/A) |
|
Details | ||
| 11/11/2022 | Nabriva Therapeutics AG | NBRV | Maintain | Outperform (N/A) |
|
Details | ||
| 9/16/2022 | Nabriva Therapeutics AG | NBRV | Maintain | Outperform (N/A) |
|
Details | ||
| 5/4/2022 | Amarin Corporation | AMRN | Downgrade | Market Perform (Outperform) |
2.74 (14.06) |
413.14% | Details | |
| 3/31/2022 | vTv Therapeutics | VTVT | Maintain | Outperform (N/A) |
|
Details | ||
| 3/31/2022 | PolarityTE | PTE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/1/2022 | Zogenix, Inc. | ZGNX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/28/2022 | Zogenix, Inc. | ZGNX | Downgrade | Market Perform (Outperform) |
26.10 (26.68) |
2.22% | Details | |
| 1/19/2022 | Zogenix, Inc. | ZGNX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/19/2021 | Flexion Therapeutics | FLXN | Downgrade | Market Perform (Outperform) |
9.12 (25.27) |
177.08% | Details | |
| 11/17/2021 | Adamas Pharmaceuticals | ADMS | Downgrade | Market Perform (Outperform) |
8.15 (8.22) |
0.86% | Details | |
| 10/28/2021 | Zogenix, Inc. | ZGNX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/14/2021 | Skylight Health Group | SLHG | New Coverage | Outperform (N/A) |
2.50 (0.58) |
-76.8% | Details | |
| 10/12/2021 | Flexion Therapeutics | FLXN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/9/2021 | Zogenix, Inc. | ZGNX | Maintain | Outperform (Market Perform) |
|
Details | ||
| 8/5/2021 | Flexion Therapeutics | FLXN | Maintain | Outperform (N/A) |
|
Details | ||
| 7/26/2021 | MiMedx Group | MDXG | New Coverage | Outperform (N/A) |
11.70 (4.50) |
-61.54% | Details | |
| 6/22/2021 | Amarin Corporation | AMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/18/2021 | Esperion Therapeutics | ESPR | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/27/2020 | Amarin Corporation | AMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/5/2020 | Amarin Corporation | AMRN | New Coverage | Outperform (N/A) |
7.62 (2.74) |
-64.04% | Details | |
| 4/8/2020 | GW Pharma | GWPH | New Coverage | Outperform (N/A) |
91.72 (218.96) |
138.73% | Details | |
| 3/23/2020 | PolarityTE | PTE | Maintain | (N/A) |
|
Details | ||
| 2/24/2020 | Esperion Therapeutics | ESPR | Downgrade | Market Perform (Outperform) |
68.35 (2.73) |
-96.01% | Details | |
| 12/27/2019 | Flexion Therapeutics | FLXN | Maintain | Outperform (N/A) |
|
Details | ||
| 10/15/2019 | Aytu Biosciences | AYTU | Maintain | Outperform (N/A) |
|
Details | ||
| 9/26/2019 | Zogenix, Inc. | ZGNX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/20/2019 | Flexion Therapeutics | FLXN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/29/2019 | Opiant Pharma | OPNT | New Coverage | Outperform (N/A) |
10.75 (20.65) |
92.09% | Details | |
| 5/6/2019 | vTv Therapeutics | VTVT | Upgrade | Outperform (Market Perform) |
1.54 (35.41) |
2199.35% | Details | |
| 1/28/2019 | PolarityTE | PTE | New Coverage | Outperform (N/A) |
17.00 (0.24) |
-98.59% | Details | |
| 10/29/2018 | Esperion Therapeutics | ESPR | Upgrade | Outperform (Market Perform) |
41.88 (68.35) |
63.2% | Details | |
| 10/3/2018 | vTv Therapeutics | VTVT | Maintain | Market Perform (N/A) |
|
Details | ||
| 9/10/2018 | Aridis Pharmaceuticals | ARDS | New Coverage | Outperform (N/A) |
9.70 (0.00) |
-100% | Details |
